Zacks Investment Research downgraded shares of CORMEDIX INC (CRMD) from N/A to NEUTRAL on July 28, 2014, with a target price of $2.20.
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease CRMD002, a diagnostic test for urinary labile iron CRMD003 (Neutrolin , an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin . CorMedix Inc. is base
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CORMEDIX INC (CRMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment